pipette
ESEspañol

Selective binders of a cotranslational folding intermediate

O. Prakash, T. B. Voisin, A. Roeselova, C. M. Jorgensen, J. S. Desmet, A. Nans, R. Davies, L. J. Walport, D. Balchin

Preprint

In the authors' words

Drug discovery efforts typically target mature, folded proteins, primarily to inhibit their function or induce their degradation. An alternative strategy would be to target incompletely folded states that are transiently populated during protein biogenesis, but whether these states contain druggable pockets was unclear. Here, we used an mRNA display approach to discover cyclic peptides that recognize a nascent polypeptide at an intermediate point during its synthesis on the ribosome. We identified peptides that bind with low-nanomolar affinity to a model nascent protein, {beta}-galactosidase, but do not detectably bind either the fully-folded protein or ribosomes synthesising different sequences. Hydrogen/deuterium exchange-mass spectrometry and cryogenic electron microscopy revealed the molecular basis for selective binding. We found that the nascent chain folds into an -helix against the ribosome surface during ongoing translation, creating a cryptic pocket together with ribosomal proteins uL23 and uL29 that is exploited by the hit peptides. Our results establish proof-of-concept for selective targeting of protein biogenesis intermediates, and provide a platform for future drug development.

Main resultThe abstract does not state a limitation.

In plain words AI summary

Drug discovery usually targets fully folded proteins, but this study explores targeting proteins during their creation. The researchers used mRNA display to find cyclic peptides that bind a partially made protein on the ribosome. These peptides bind tightly to beta-galactosidase during synthesis, but not to the finished protein or other ribosomes. Imaging showed the growing protein forms a hidden pocket with ribosomal proteins uL23 and uL29 that the peptides exploit. This work demonstrates that protein creation intermediates can be selectively targeted for future drug development.

Written by Kimi K2.5 using only the abstract above. Jev checked that every sentence is supported by the abstract sentences it cites, and removed any that were not. Point at a sentence to highlight its source.

Appeared: Tuesday, November 3. bioRxiv. Preprint, not yet peer-reviewed.

DOI: 10.64898/2026.10.30.763055